Intralesional Rituximab in the Treatment of Refractory Oral Pemphigus Vulgaris | Zendy

Keshavamurthy Vinay | Zendy; Amrinder J. Kanwar | Zendy; Ankit Mittal | Zendy; Sunil Dogra | Zendy; Ranjana W. Minz | Zendy; Takashi Hashimoto | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intralesional Rituximab in the Treatment of Refractory Oral Pemphigus Vulgaris

Author(s) -

Keshavamurthy Vinay,

Amrinder J. Kanwar,

Ankit Mittal,

Sunil Dogra,

Ranjana W. Minz,

Takashi Hashimoto

Publication year - 2014

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2014.3674

Subject(s) - medicine , rituximab , pemphigus vulgaris , adverse effect , pemphigus , refractory (planetary science) , corticosteroid , gastroenterology , surgery , dermatology , lymphoma , physics , astrobiology

Oral lesions of pemphigus vulgaris are usually recalcitrant and respond slowly to treatments. Corticosteroid injection is considered to be the most effective local treatment in oral pemphigus vulgaris. However, intralesional corticosteroids are not effective in all remnant lesions. In 3 such patients with pemphigus vulgaris, we evaluated the utility of 2 injections (on days 1 and 15) of intralesional rituximab, 5 mg/cm², in terms of accelerated healing, limitation of the use of systemic immunosuppressants, and reduction of their adverse effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research